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Background: Kawasaki disease (KD) is a vasculitis of early childhood mimicking
several infectious diseases. Differentiation between KD and infectious diseases is
essential as KD’s most important complication—the development of coronary artery
aneurysms (CAA)—can be largely avoided by timely treatment with intravenous
immunoglobulins (IVIG). Currently, KD diagnosis is only based on clinical criteria. The aim
of this study was to evaluate whether routine C-reactive protein (CRP) and additional
inflammatory parameters myeloid-related protein 8/14 (MRP8/14 or S100A8/9) and
human neutrophil-derived elastase (HNE) could distinguish KD from infectious diseases.
Methods and Results: The cross-sectional study included KD patients and children
with proven infections as well as febrile controls. Patients were recruited between July
2006 and December 2018 in Europe and USA. MRP8/14, CRP, and HNE were assessed
for their discriminatory ability by multiple logistic regression analysis with backward
selection and receiver operator characteristic (ROC) curves. In the discovery cohort, the
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combination of MRP8/14+CRP discriminated KD patients (n = 48) from patients with
infection (n = 105), with area under the ROC curve (AUC) of 0.88. The HNE values did
not improve discrimination. The first validation cohort confirmed the predictive value of
MRP8/14+CRP to discriminate acute KD patients (n = 26) from those with infections (n
= 150), with an AUC of 0.78. The second validation cohort of acute KD patients (n = 25)
and febrile controls (n= 50) showed an AUC of 0.72, which improved to 0.84 when HNE
was included.
Conclusion: When used in combination, the plasma markers MRP8/14, CRP, and HNE
may assist in the discrimination of KD from both proven and suspected infection.
Keywords: kawasaki disease, infectious disease, vasculitis, coronary aneurysm, biomarker, bacterial infection,
viral infection
INTRODUCTION
Kawasaki disease (KD) is a systemic vasculitis of early childhood
occurring mainly in children under the age of 5 years. The
origin of the disease is still unknown. The current paradigm is
that KD is caused by an immunologic reaction elicited by an
(infectious) trigger in genetically predisposed children. KD’smost
important complication is the development of coronary artery
aneurysms (CAA), affecting 25% of the untreated patients (1).
This makes KD themost common cause of acquired heart disease
in developed countries in children. The risk of CAA development
is decreased 5-fold when the patient is treated with high-dose
intravenous immunoglobulin (IVIG) and oral aspirin within 10
days of disease onset (1).
No specific diagnostic laboratory test for KD is available to
date and KD is diagnosed based on the presence of clinical
criteria, including prolonged fever, rash, lymphadenopathy,
conjunctival injection, and abnormalities of mucosae and
extremities. However, KD can be easily misdiagnosed due to the
symptomatology resembling several infections (1–3) and the fact
that bacterial and viral pathogens are regularly found in KD
patients (2). Additionally, atypical or incomplete KD may also
hinder the diagnosis. Therefore, KD diagnosis and initiation of
treatment are commonly delayed, with a resulting increased risk
of CAA development.
A rapid blood test to distinguish KD from infection, which
enables the diagnosis and early treatment initiation, would
reduce the burden of KD-related heart disease. Up to now, studies
on surrogate plasma markers for acute KD have not included
adequate febrile infection controls (4–6). While previous studies
have shown promise that KD patients can be discriminated
from febrile controls using gene expression (5), findings based
on proteins may be more easily translatable into tests with
immediate clinical utility.
We selected plasma biomarkers shown to be increased in KD
patients and combined these markers to investigate whether a
multi-protein test would discriminate KD from infection. We
focused on C-reactive protein (CRP) and two neutrophil-derived
proteins, myeloid-related protein 8/14 (MRP8/14) and human
neutrophil elastase (HNE). MRP8/14 (S100A8/9 or calprotectin),
a cytoplasmic protein found in neutrophils, and to a much lesser
extent in monocytes, belongs to a family of calcium-binding
proteins (7). MRP8/14 is released into the extracellular space
upon cell activation, operating as a damage-associated molecular
pattern (DAMP). MRP8/14 is recognized as a biomarker for
several inflammatory diseases, including inflammatory bowel
disease, and rheumatoid arthritis (8–10). In acute KD patients,
elevated MRP8/14 levels have been previously reported, but in
studies with no febrile controls (4, 11, 12). HNE, a well-known
marker of neutrophil activation, is a neutrophil-specific serine
protease located in the neutrophil azurophilic granules. HNE has
been shown to be increased in the acute phase of KD compared
to afebrile healthy controls (13).
CRP, an acute inflammatory protein that is synthesized
in hepatocytes, binds to polysaccharides on microorganisms,
triggering the classical complement pathway and initiating an
innate immune response. CRP is commonly used as a biomarker
as it is elevated during both acute infection and inflammation
(14, 15).
The aim of this study was to evaluate whether MRP8/14,
CRP, or HNE may act as possible biomarker(s) to diagnose acute
(including incomplete) KD in febrile children. We analyzed the
MRP8/14 levels before and after treatment in paired samples
available from KD patients and investigated whether MRP8/14,
CRP, and/or HNE could be used as a marker for the prediction of
responsiveness to IVIG treatment and/or of CAA development
during acute KD.
METHODS
We have used three cohorts of KD patients: a discovery
cohort and two independent validation cohorts. For comparison,
we used prospective samples collected in independent studies
from febrile children diagnosed with acute bacterial and viral
infections as well as those suspected of infection.
KD Patients
Children (<18 years old) with acute KD based on the criteria
of the American Heart Association (16) were recruited at the
University Medical Center in Amsterdam [Amsterdam UMC,
location Academic Medical Center (AMC)] and participating
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hospitals in the Netherlands as approved by the Medical Ethical
Board of the AMC (no. NL41023.018.12) (for the discovery
cohort). Patients were recruited between July 2006 andDecember
2018. For our first validation cohort, KD samples were included
from the ongoing UK Kawasaki study “Genetic determinants of
Kawasaki Disease for susceptibility and outcome” (13/LO/0026).
This study recruits acutely unwell children with KD during
hospital admission in participating hospitals around the UK.
Our second validation cohort included KD patients who met the
American Heart Association criteria for complete or incomplete
KD cared for at Rady Children’s Hospital, San Diego, CA.
The medical records of KD patients were reviewed and the
clinical details recorded. CAA were defined by worst ever z
scores: CA dimensions as standard deviation units normalized
for body surface area (17). CAA was defined as a coronary z
score ≥2.5.
EDTA plasma samples of the KD discovery cohort were
collected before and, if available, after IVIG treatment. All
samples taken within 14 days from disease onset (fever) were
selected for the analysis and only those within 2 days after the
start of IVIG were included as “acute,” except for the analysis
of the paired samples of “acute disease” and convalescent after
IVIG, from which the samples were taken during convalescence
up to 1 year after the onset of disease. In the validation cohorts,
samples from the “acute disease” were all samples before IVIG
was administered.
Febrile Patients With Definite Infections
For the discovery and the first validation cohorts, we compared
KD patients to children presenting with acute febrile illness
caused by a bacterial or viral illness. All children with a bacterial
infection had amicrobiologically confirmed pathogen detected in
a normally sterile site and a consistent corresponding syndrome,
including sepsis, meningitis, osteomyelitis, or pneumonia. All
children with a viral illness had a detected viral pathogen,
confirmed with culture, molecular, and/or immunofluorescent
testing, and a consistent corresponding syndrome, without
hallmarks of bacterial illness. In the viral infection group, a CRP
of <60 was used to define a set of patients with a confident viral
infection, as described in (18).
Discovery cohort
EDTA plasma samples from children (<18 years old) were
collected at the first available time after presentation (within
48 h), in European hospitals participating in the EUCLIDS
Consortium (19) (EU-Childhood Life-Threatening Infectious
Disease Study; www.euclids.eu) and in the GENDRES (GENetic,
Vitamin D and RESpiratory Infections Research Network; www.
gendres.org) (20). Patients were included between December
2009 and May 2014. Clinical details were recorded as part of
the study, including gender, age at disease onset, hospitalization,
and details about the type of disease and the invasive pathogen
involved when cultured from sterile sites.
First Validation Cohort
Patients were included after local approval in the international
study on febrile children (PERFORM; https://www.perform2020.
org/). Overall, patients were included between July 2012 and
December 2018. EDTA plasma samples were collected at
presentation to hospital in the Emergency Department or ward.
Clinical details were recorded as described above.
Febrile Patients With Suspected Infections
For the second validation cohort, we compared KD patients
to children presenting with acute febrile illness with
suspected infection.
Second Validation Cohort
Febrile control patients were recruited from the Emergency
Department at Rady Children’s Hospital, San Diego, CA. The
study protocol was reviewed and accepted by the UCSD
institutional review board. Parental consent was obtained, where
appropriate. The inclusion criteria for the febrile controls were
fever for at least 3 days, no use of steroids, and at least one
clinical sign of KD. Review of the medical records at least 1
month after the onset of fever retrospectively confirmed that
these patients all had a self-limited illness that required no anti-
infective treatment and were deemed likely due to a non-specific
viral illness. The majority of these patients had been initially
referred to the hospital to rule out KD.
Healthy Controls
After informed consent, EDTA-anticoagulated blood samples
from healthy volunteer donors were obtained via an internal
system at Sanquin (the Dutch national blood bank) after
consulting the Medical Ethical Committee from the Academic
Medical Center Amsterdam. All procedures were conducted in
accordance with the 1975 Declaration of Helsinki as revised
in 2013, and local ethics approval were obtained within the
PERFORM Study mentioned above. Median age was 37.8
(interquartile range, IQR = 37.8–58.7) years and 39.5% were
male. No clear age-defined or gender-related effects were seen in
the baseline values (13).
Analysis of Neutrophil Activation Markers
MRP8/14 wasmeasured in a new enzyme-linked immunosorbent
(ELISA) assay developed at Sanquin. All washes between the
incubation steps were done with phosphate-buffered saline
(PBS) 0.02% Tween-20 using Elx 405 (BioTek Instruments).
Anti-human MRP8/14 monoclonal mouse IgG1 antibody, clone
27E10 (0.5µg/ml in 0.1M carbonate buffer, pH 9.6; BMA
Biomedicals, Augst, Switzerland), was used to coat a Maxisorp
Nunc-immunoplate (Thermo Scientific). After overnight static
incubation at room temperature and wash, serum pooled from
30 healthy donors was added to give a calibration curve [diluted
2-fold from 8.5 ng/ml (v/v) in TTG (10mM Tris, 150mM NaCl,
10mM CaCl2, 0.1% Tween-20, 0.2% gelatin, pH 7.4)]. As a
positive control, the pooled sera was spiked with 10µg/ml
recombinant MRP8/14 (Hycult Biotech, Plymouth Meeting,
PA, USA) and diluted to 0.1% (v/v). The samples, positive
control, and calibration curve were incubated for 1 h. After
washing, 500 ng/ml biotinylated mouse monoclonal IgG1 anti-
MRP8/14 antibody, clone S36.48 (BMA Biomedicals), was added.
After incubation for 1 h, further washing, and the addition of
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streptavidin conjugated to poly-horseradish peroxidase [poly-
HRP, 0.1% (v/v)] for 30min followed by 100µg/ml 3,3′,5,5′-
tetramethylbenzidine (TMB; Merck Chemicals) in 0.11M
sodium acetate, pH 5.5, with 0.003% (v/v) H2O2, and 2M
H2SO4, absorbance was measured at 450/540 nm. The results
are expressed in nanograms per milliliter by reference of the
calibration curve.
Plasma HNE is not present in blood alone, but in complex
with α1-antitrypsin (α1AT). Therefore, plasma HNE was
measured as HNE–α1AT complexes. CRP and HNE–α1AT
complexes were determined by ELISAs, as described previously
(21, 22).
Statistical Analysis
Data were assessed to determine normal distribution. Differences
in the MRP8/14, CRP, and HNE values between the patient
cohorts were plotted as the median + IQR. Log10-transformed
data were used with respect to linearity for further statistical
analyses on the predictive values of the markers.
A logistic regression analysis with backward selection was
used to examine the predictive value (odds ratio) of the candidate
markers for acute KD vs. infections and for KD vs. bacterial and
KD vs. viral infections.
Receiver operating characteristic (ROC) curves were plotted
from the predictive markers derived from the logistic regression
analysis. The area under the ROC curve (AUC) from both
the individual candidate markers as well as a combination of
candidate markers (the predicted probability) was used to check
for discriminatory value. The best discriminatory cutoff value
was calculated with Youden’s J Statistic. The cutoff from the
discovery cohort was applied to the validation cohorts and the
corresponding sensitivity and specificity with 95% confidence
intervals (CI) were calculated. Using predicted probabilities
based on the discovery model, ROC curves in the validation
cohorts were plotted and AUCs were compared to the AUC’s
from the discovery cohort.
For the analysis of the MRP8/14 levels pre- and post-IVIG
treatment, a Wilcoxon signed-rank test was performed in paired
samples. The predictive capacities of the markers for treatment
response and CAA development in acute KD patients were
calculated by a logistic regression with backward selection.
A p < 0.05 was considered to be statistically significant. SPSS
version 24.1 (IBM, Armonk, NY) and R version 3.4.4 (The R
Foundation for Statistical Computing, Vienna, Austria) were
used for all statistical analyses.
RESULTS
Our discovery cohort consisted of 48 patients with acute KD
(27 pre-IVIG treatment and 21 shortly after IVIG treatment had
been administered, within 3 days). Of these acute patients, 10
were diagnosed with incomplete KD. In total, 105 patients were
included with infections (40 patients with viral infections and
65 patients with bacterial infections). Our first validation cohort
consisted of 26 patients with acute KD (pre-IVIG treatment)
and 150 patients with infections (75 bacterial and 75 viral)
diagnosed at different centers in Europe. The second validation
cohort consisted of 50 KD patients (with paired measurements
pre- and post-IVIG treatments, i.e., acute vs. convalescent
disease) and 50 febrile control patients. The demographic and
clinical characteristics of all patients are shown in Table 1.
Supplemental Table 1 provides a more detailed overview of the
patients with definite (i.e., proven) infections in our discovery
and first validation cohorts.
MRP8/14 and CRP Discriminate Between
Acute KD and an Infection
First, we aimed to determine the differences in MRP8/14, CRP,
and HNE in the discovery cohort (Figures 1A–C). MRP8/14,
CRP, and HNE were significantly different between the KD and
infectious patients. The results from our two validation cohorts
are shown in Supplemental Figure 1. When assessing KD vs.
bacterial infections only, the MRP8/14 levels were significantly
elevated in KD. In the bacterial patients, a high- and low-
MRP8/14 group could be distinguished. The patient group with
the high MRP8/14 levels did not have a pathogen or diagnosis
in common. No correlation was found between the MRP8/14 or
HNE and absolute neutrophil counts (data not shown).
Multiple logistic regression analysis with backward selection
on the discovery cohort showed that elevated levels of MRP8/14
(log10 OR = 7.7, 95% CI = 3.2–18.5) and CRP (log10 OR =
5.1, 95% CI = 1.7–14.7) were predictive for acute KD over an
infection (p< 0.001). HNEwas removed from the analysis during
backward selection.
ROC curves were plotted for the predictive ability of MRP8/14
and CRP to discriminate between acute KD and an infection. The
AUC for MRP8/14 was 0.86 (95% CI = 0.78–0.93, p < 0.001),
with a sensitivity of 70% and a specificity of 91% and cutoff of
6,540 ng/ml. For CRP, the AUC was 0.76 (95% CI = 0.68–0.85, p
< 0.001), with a sensitivity of 78% and a specificity of 67% and
cutoff of 43.9 mg/l. The ROC curve of the predicted probability
of KD when MRP8/14 and CRP were used together was 0.88
(95% CI = 0.82–0.95, p < 0.001), with a sensitivity of 85% and
a specificity of 83% (Figure 2A). The optimal cutoff from the
discovery cohort (predicted KD probability of 0.37 or higher)
was applied to the first validation cohort and the corresponding
sensitivity and specificity were determined, showing a sensitivity
of 73% and a specificity of 77%. The ROC curve from the
predicted probability of KD when both MRP8/14 and CRP were
used in the first validation cohort showed an AUC of 0.81 (95%
CI= 0.73–0.88) (Figure 2B).
The same optimal cutoff was also applied to our second
validation cohort, with patients from the USA. Here, we found
a sensitivity of 74% and a specificity of 62%. The ROC curve
with both MRP8/14 and CRP showed an AUC of 0.72 (95% CI
= 0.62–0.82) (Figure 2C).
Meta-Analysis of All Cohorts
In this study, we wanted to test the values of CRP, MRP8/14,
and HNE in predicting KD over an infection. A summary
of all the AUCs and the sensitivity and specificity values
for MRP8/14+CRP in the different cohorts is shown in
Supplemental Table 2. Three independent cohorts showed a
strong predicted probability of KD over an infection when
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TABLE 1 | Demographic and clinical characteristics of the patients in the acute Kawasaki disease, bacterial, and viral infections cohort and in the discovery and validation cohorts.
Discovery cohort First validation cohort Second validation cohort
Kawasaki disease, n = 48
(27 pre-IVIG,
21 post-IVIG)
Bacterial infections,
n = 65
Viral infections,
n = 40
Kawasaki disease,
n = 26
Bacterial
infections,
n = 75
Viral infections,
n = 75
Kawasaki disease,
pre-IVIG,
n = 50
Kawasaki disease,
post-IVIG,
n = 50
Febrile control,
n = 50
% Male (n) 64.4% (31) 47.7% (31) 45% (18) 69.2% (18) 54.7% (41) 57.3% (43) 46% (23) 46% (23) 48% (24)
Age at sample
date (years,
median +)
2.1 (1.1–4.5) 9 (3–14.3) 1.4 (0.2–3.6) 2.8 (1–3.8) 4.58 (0.8–7.5) 3 (0.8–6.9) 2.7 (1.6–5.5) 2.7 (1.6–5.5) 3.4 (1.2–5.2)
Days of fever
before hospital
admission (days,
median +)
8 (6–11) 1 (0–2) 1 (0–2) 6 (5–8) 1 (1–5) 2 (1–5) 5 (4–7) 19 (17–21) 5 (4–7)
Days until IVIG
treatment (days)
<10 days Not applicable Not applicable <10 days Not applicable Not applicable <10 days Not
applicable
Not applicable
% CAA (n) CAA: 25% (12)
Giant: 8.3% (4)
Not applicable Not applicable CAA: 15.4% (4)
Giant: 0%
Not applicable Not applicable CAA: 24% (12)
Giant: 0%
CAA: 24% (12)
Giant: 0%
Not applicable
% Unresponsive to
first IVIG course (n)
25% (12) Not applicable Not applicable 23% (6) Not applicable Not applicable 4% (4) Not
applicable
Not applicable
% Ethnicity Caucasian: 68.6%;
Asian: 4.2%;
Other: 4.2%;
Unknown: 23%
Caucasian: 80%;
Asian: 1.5%;
Other: 4.5%;
Unknown: 14%
Caucasian:
62.5%;
Asian: 12.5%;
Hispanic: 12.5%;
Other: 12.5%
Caucasian: 23%;
Asian: 11.5%;
African: 34.5%;
Other: 15.5%;
Unknown: 15.5%
Caucasian:
53.3%;
Asian: 1.3%;
Hispanic: 21.3%;
Mixed: 1.3%;
Other: 10.6%
Caucasian: 56%;
Asian: 10.6%;
Hispanic: 21.3%;
Mixed: 1.3%;
Other: 10.6%
Caucasian: 12%;
Asian: 18%;
Hispanic: 42%;
Mixed: 28%
Caucasian: 12%;
Asian: 18;
Hispanic: 42%;
Mixed: 28%
Caucasian: 20%;
Asian: 8%;
Hispanic: 42%;
Mixed: 22%;
Unknown: 8%
Giant aneurysm is defined by a z score >2.5.
CAA, coronary artery aneurysm.
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FIGURE 1 | Myeloid-related protein 8/14 (MRP8/14) (A), C-reactive protein (CRP) (B), and neutrophil-derived elastase (HNE) (C) levels in the discovery cohort.
Patients with acute Kawasaki disease are compared to patients with infections and, more specifically, patients with either bacterial or viral infections. Each dot is a
unique patient. Dotted line represents the 75% concentration in the healthy controls: 400 ng/ml MRP8/14, 2.7 mg/l CRP, and 37.3 ng/ml HNE. Median levels +
interquartile ranges are listed below the figure. Differences were calculated with the Kruskal–Wallis test, followed by Dunn’s multiple comparisons test. **p < 0.005,
****p < 0.001; ns, not significant.
combining MRP8/14 and CRP. HNE was eliminated in the
analysis after the logistic regression with backward selection in
our discovery cohort. By analyzing all three cohorts together
in a meta-analysis, we created a large cohort with a range of
ethnicity. This meta-cohort was used to test our model and see
whether revision or extension of the existing prediction model
was necessary.
Our large cohort consisted of 124 acute KD patients and
305 febrile patients (proven infections combined with the
“undefined” febrile controls). We re-estimated the effects of our
current model and investigated a possible extension with HNE
in this large cohort. Multiple logistic regression analysis showed
that elevated levels of MRP8/14 (log10 OR = 5.5, 95% CI = 3.1–
9.6), CRP (log10 OR = 2.4, 95% CI = 1.3–4.1), and HNE (log10
OR = 2.3, 95% CI = 1.3–4.0) were predictive of acute KD over
an infection (p < 0.001). Although HNE was not included in
the initial model, in our large cohort, we saw a significant effect
of HNE in predicting KD over an infection. The discriminatory
power of the model with MRP8/14, CRP, and HNE showed an
AUC of 0.84 (95% CI = 0.80–0.88), with a sensitivity of 74% and
a specificity of 83% (Figure 3).
MRP8/14 as a Marker for Treatment
Response and CAA Development
Prediction of IVIG resistance and risk of developing CAA by
biomarkers would greatly aid clinical decision making. In the
discovery cohort and the second validation cohort, we compared
the levels of MRP8/14 in paired samples and in those with and
without CAA.
A total of 25 children had paired measurements pre-
IVIG treatment and during convalescence [median of 49
days (IQR = 27–155 days) after disease onset]. The samples
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FIGURE 2 | Receiver operator characteristic (ROC) curves of the discovery cohort (A), first validation cohort (B), and the second validation cohort (C) of MRP8/14 and
CRP together for discrimination between acute Kawasaki disease and infections. The corresponding areas under the ROC curve (AUCs) are listed within the panels.
collected prior to IVIG administration showed significantly
higher levels of MRP8/14 (median = 10,400 ng/ml, IQR =
3,500–42,500 ng/ml) compared to the samples collected during
post-IVIG convalescence (median = 1,600 ng/ml, IQR = 300–
5,600 ng/ml, p < 0.0001) (Figure 4A).
In our second validation cohort, a total of 50 patients
had paired measurements before IVIG treatment and during
convalescence [median of 20 days (IQR = 17–22 days)
after disease onset]. Again, the samples pre-IVIG treatment
showed significantly higher levels of MRP8/14 (median =
8,398 ng/ml, IQR = 4,506–16,025 ng/ml) compared to the post-
IVIG convalescence state (median = 836 ng/ml, IQR = 450.8–
1,924 ng/ml, p < 0.0001) (Figure 4B). The same significant
decrease was seen in CRP and HNE in both the discovery and
validation cohorts (data not shown). A logistic regression analysis
showed that neither MRP8/14 nor one of the other markers was
predictive of clinical IVIG response.
As CAA are the most prevalent complications of KD, we
combined all our KD samples and assessed whether theMRP8/14
values were elevated in patients with CAA, but no significant
differences were seen (Supplemental Figure 2). Also, a logistic
regression analysis showed that none of the markers was
predictive of CAA development (data not shown).
DISCUSSION
To date, a rapid protein test to distinguish KD from infection
is not available. Different studies have been conducted in the
search for a biomarker, but have failed to find a single and reliable
biomarker. This includes studies on a broad panel of routinely
used parameters (23), antibody profiling using of Escherichia coli
proteome microarrays, (24), or the identification of candidate
biomarkers using multiplex cytokine and protein arrays (25). In
this study, we have investigated inflammation-related plasma-
derived biomarkers to identify pediatric patients with acute KD
among their febrile peers with a proven or suspected infection.
Our most important finding was that a combined measurement
of MRP8/14 and CRP, and possible HNE, was indicative of KD,
discriminating KD from probable infections in febrile children.
When applying the optimal cutoffs to the validation cohorts,
we observed an impaired specificity of the markers, with an
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overestimation of KD. This might be a result of the differences
in pathogens (Supplemental Table 1). The different case/control
ratios in the three cohorts could possibly influence the estimated
sensitivities, specificities, and the derived AUCs, but these effects
are not systemic (26). In the discovery cohort, we included 21 KD
patients in the acute group, up to 3 days after IVIG treatment.
We split the KD group into pre-IVIG treatment and shortly
after IVIG treatment and compared the levels of MRP8/14, CRP,
and HNE in these two subgroups. There was no difference seen
FIGURE 3 | Receiver operator characteristic (ROC) curves of MRP8/14, CRP,
and HNE combined in the meta-analysis. The corresponding area under the
ROC curve (AUC) is listed within the panel.
(data not shown), showing that these biomarkers are stable in the
acute phase of KD up to 3 days after IVIG treatment. What we
have noticed before is that HNE remains detectable in KD when
measured at regular time points up to 3 months following the
acute stage (13) and that CRP remains elevated in KD patients
with CAA more than 5 years after disease onset (27). This
indicates that low-grade inflammation may indeed be present
subclinically much longer than previously thought.
It is highly encouraging that candidate plasma markers for
acute KD in febrile children have been found and validated
against common bacterial and viral infections. Together with
the clinical manifestations at presentation of these patients,
the combined use of these markers will enable physicians to
be more confident in their KD diagnosis. Although MRP8/14
is significantly lower after treatment with IVIG in the paired
samples, its pretreatment levels could not predict clinical IVIG
response in our discovery cohort and in the second validation
cohort. We also did not find a correlation of the MRP8/14 (nor
CRP and HNE) levels with CAA.
The most important consequence of a quick and correct KD
diagnosis is the ability to promptly initiate IVIG treatment and,
thereby, reduce the risk of CAA development. CRP is used, but
is non-discriminatory. HNE has been used before in a previous
study of our group by (13). A few studies have reported on
the MRP8/14 levels in children with KD. Hirono et al. found
increased MRP8/14 concentrations before IVIG as compared
to post-IVIG in 45 IVIG-responding KD patients, whereas the
levels did not decrease after IVIG in 16 IVIG non-responders
(12). Four weeks after IVIG treatment, these patients still showed
higher MRP8/14 concentrations compared to IVIG responders.
Abe et al. found increased MRP8/14 levels in 32 KD patients
before IVIG treatment compared to after IVIG treatment and
compared to controls with fever of unknown origin (4), which
may correlate with the epigenetic regulation of S100A genes
(28). Viemann et al. found that the MRP8/14 concentrations
dropped significantly within 24 h after IVIG treatment in 21
KD patients (11). After 1 month, the concentrations reached
FIGURE 4 | Differences in the MRP8/14 levels in acute Kawasaki disease (KD) and convalescent in 25 paired samples from the discovery cohort (A) and 50 paired
samples from the second validation cohort (B). In the discovery cohort, one sample above 30,000 ng/ml MRP8/14 was excluded in this graph. Analyzed by a
Wilcoxon matched-pairs test. ***p < 0.0001.
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the values of their healthy controls. These authors found that
the endothelium of the coronary arteries from the myocardial
sections of three deceased KD patients were almost completely
coated when stained with antibodies against MRP8 or MRP14
(S100A8 or S100A9). Recent investigation using a proteomic
approach documented elevated levels of MRP8/14 decades after
acute KD in patients with giant aneurysms (29). The variations
in the correlations with CAA development may depend on
technical differences in measuring CAA dimensions, but more
likely will be determined by statistical power (or lack thereof)
because of the small sample size of these studies, the non-
prospective study design, and maybe also because of genetic
differences in the cohorts tested. A conclusion as to whether
the biomarker(s) really have predictive values will demand
prospectively designed large studies to settle the diverse findings
to date.
There are indications that MRP8/14 is a regulator of
vascular inflammation (30) and is found to be elevated during
different types of vasculitis (31, 32) and during vascular injury
(33, 34). Furthermore, MRP8/14 has been shown to impair
endothelial integrity (35), and high amounts of MRP8/14
in the coronary endothelium of KD patients are observed
(11). Apart from acting as a DAMP, the special role of
MRP8/14 during vascular inflammation could be a reason for
its remarkable elevation during the acute vasculitis of KD.
MRP8/14 is released from phagocytes after contact with the
inflamed endothelium (36) and might also be released from the
endothelium itself.
In our study, we have found that MRP8/14 and CRP, and
possibly HNE, could be potentially used to help physicians
diagnose KD in febrile children, enabling prompt treatment
and lowering the risk of CAA formation. We were able
to substantiate our findings in the validation cohorts,
collected according to international diagnostic criteria.
Additional prospective studies should now follow to more
routinely perform our model of markers in pediatric patients
with prolonged fever to further confirm our findings.
The value of the combined tests may also prove to be
helpful in the case of incomplete KD to decide whether
IVIG treatment seems justified instead of further clinical
observation waiting for microbiological results or the effect
of antibiotics.
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